Vaccinex, Inc. (VCNX)
USD 1.0
(66.67%)
USD 1.0
(66.67%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.28 Million USD | 78.19% |
| 2022 | -5.9 Million USD | 27.97% |
| 2021 | -8.19 Million USD | -490.71% |
| 2020 | -1.38 Million USD | 50.0% |
| 2019 | -2.77 Million USD | 50.59% |
| 2018 | -5.61 Million USD | -310.97% |
| 2017 | -1.36 Million USD | -119.07% |
| 2016 | -624 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -111 Thousand USD | 96.02% |
| 2024 Q1 | -2.78 Million USD | -116.38% |
| 2023 Q2 | -1.54 Million USD | 46.79% |
| 2023 Q1 | -2.89 Million USD | 50.97% |
| 2023 FY | -1.28 Million USD | 78.19% |
| 2023 Q4 | -1.28 Million USD | -815.56% |
| 2023 Q3 | 180 Thousand USD | 111.68% |
| 2022 Q4 | -5.9 Million USD | 11.08% |
| 2022 Q3 | -6.64 Million USD | 40.33% |
| 2022 Q1 | -16.47 Million USD | -100.93% |
| 2022 FY | -5.9 Million USD | 27.97% |
| 2022 Q2 | -11.13 Million USD | 32.43% |
| 2021 Q3 | -12.6 Million USD | 32.81% |
| 2021 Q4 | -8.19 Million USD | 34.96% |
| 2021 Q1 | -25.96 Million USD | -1770.39% |
| 2021 FY | -8.19 Million USD | -490.71% |
| 2021 Q2 | -18.76 Million USD | 27.73% |
| 2020 Q2 | 608 Thousand USD | 124.41% |
| 2020 Q4 | -1.38 Million USD | 82.8% |
| 2020 FY | -1.38 Million USD | 50.0% |
| 2020 Q1 | -2.49 Million USD | 10.27% |
| 2020 Q3 | -8.06 Million USD | -1426.97% |
| 2019 Q4 | -2.77 Million USD | 67.64% |
| 2019 Q2 | -5.27 Million USD | 40.96% |
| 2019 Q1 | -8.94 Million USD | -59.17% |
| 2019 FY | -2.77 Million USD | 50.59% |
| 2019 Q3 | -8.57 Million USD | -62.49% |
| 2018 Q1 | -1.69 Million USD | -24.07% |
| 2018 FY | -5.61 Million USD | -310.97% |
| 2018 Q4 | -5.61 Million USD | 50.1% |
| 2018 Q3 | -11.25 Million USD | -53509.52% |
| 2018 Q2 | -21 Thousand USD | 98.76% |
| 2017 Q1 | 1.66 Million USD | 0.0% |
| 2017 Q4 | -1.36 Million USD | 0.0% |
| 2017 FY | -1.36 Million USD | -119.07% |
| 2016 FY | -624 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| America Great Health | 1.81 Million USD | 170.92% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | 66.239% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | 202.711% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 103.998% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | -37.167% |
| Better Therapeutics, Inc. | -860 Thousand USD | -49.767% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 94.585% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | 492.156% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 128.184% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 77.881% |
| Evelo Biosciences, Inc. | 3.19 Million USD | 140.275% |
| Evolutionary Genomics, Inc. | 3.16 Million USD | 140.674% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 125.75% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 100.961% |
| Innovation1 Biotech Inc. | 179.15 Thousand USD | 818.951% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 110.439% |
| Molecular Templates, Inc. | 707 Thousand USD | 282.178% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | 393.766% |
| NexImmune, Inc. | -3.13 Million USD | 58.898% |
| Orgenesis Inc. | 21.78 Million USD | 105.913% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | 149.235% |
| Point of Care Nano-Technology, Inc. | -498.00 USD | -258534.538% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 72.658% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | -933.915% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 101.162% |
| Statera Biopharma, Inc. | 14.41 Million USD | 108.934% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 83.044% |
| Trevena, Inc. | 2.25 Million USD | 157.042% |
| Vaxxinity, Inc. | 10.13 Million USD | 112.712% |
| Vicapsys Life Sciences, Inc. | 344.44 Thousand USD | 473.934% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 109.729% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | 1889.834% |